C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma

Agro Food Industry Hi-Tech

Volumn 20, Issue 3 SUPPL., 2009, Pages 382-384

  Maleddu, Alessandra ^a   Pantaleo, Maria A ^a   Castellucci, Paolo ^b   Astorino, Maria ^a   Nanni, Cristina ^b   Nannini, Margherita ^a   Busato, Fiorenza ^c   Di Battista, Monica ^a   Farsad, Mohsen ^b   Lodi, Filippo ^d   Boschi, Stefano ^d   Fanti, Stefano ^b   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Nudear Medicine Service

^c Malpighi Radiology Unit

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

PET; Renal cell carcinoma; Sunitinib; Treatment response prediction

Indexed keywords

AMINO ACIDS; CYTOLOGY; ENZYME INHIBITION; FORECASTING; PATIENT TREATMENT; POLYETHYLENE TEREPHTHALATES; TUMORS;

EARLY PREDICTION; FUNCTIONAL TUMORS; GASTROINTESTINAL STROMAL TUMORS; INTERESTING POINTS; RENAL CELL CARCINOMA; SUNITINIB; TREATMENT RESPONSE; TYROSINE KINASE INHIBITOR;

CELLS;

EID: 67849097067     PISSN: 17226996     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356:115-124, 2007.
2. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM: F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol, 21: 3995-4000, 2003.
3. Soloviev D, Fini A, Chierichetti F, Al-Nahhas A, Rubello D: PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging, 35:942-949, 2008.
4. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD: Carbon-11-acetate PET imaging in renal disease. J Nucl Med, 36:1595-1601, 1995.
5. Kotzerke J, Linné C, Meinhardt M, Steinbach J, Wirth M, Baretton G, Abolmaali N, Beuthien-Baumann B: [1-(11)-C] Acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging, 34: 884-888, 2007.
6. Weber WA, Wieder H: Monitoring chemotherapy and radiotherapy of solid tumours. Eur J Nucl Med Mol Imaging, 33 (Suppl 11): 27-37, 2006.
7. Van de Abeele A, Melenevsky Y, de Vries D, Manola P, Dileo P, Tetrault R, Baum C, Badawi R, Demetri G: Imaging kinase target inhibition with SU11248 by FDG-PET in patients with imatinib-resistant gastrointestinal stromal tumors. Proc Am Soc Clin Oncol, 23: 817s (abstract 9006), 2005.
8. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A: 18FDG- positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer, 39:2012-2020, 2003.
9. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, Mutri V, Funaioli C, Sperandi F, Giaquinta S, Martoni AA: The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarci-noma treated with chemotherapy plus cetuximab. Gastric Cancer, 10: 221-227, 2007.
10. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, Ishizuka T, Endo K, Mori M: Usefulness of FDG-PET for early prediction of the response to gefitinib in non-smal cell lung cancer. Lung Cancer, 59:203-210, 2008.
11. Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwing KA, Jain RK: Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol, 4:316-321, 2007.
12. Pantaleo MA, Nannini M, Maleddu A, Fanti S, AmbrosiniV, Nanni C, Boschi S, Biasco G: Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev, 34:103-121, 2008.